Related Experiment Video
Updated: Apr 8, 2026

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases
Published on: November 22, 2024
PKC412 normalizes mutation-related keratin filament disruption and hepatic injury in mice by promoting keratin-myosin
Raymond Kwan1,2, Lu Chen1,3, Koksun Looi1
1Departments of Molecular & Integrative Physiology and of Medicine, University of Michigan, Ann Arbor, MI.
Unlabelled:
Keratins, among other cytoskeletal intermediate filament proteins, are mutated at a highly conserved arginine with consequent severe disease phenotypes due to disruption of keratin filament organization. We screened a kinase inhibitor library, using A549 cells that are transduced with a lentivirus keratin 18 (K18) construct, to identify compounds that normalize filament disruption due to K18 Arg90Cys mutation at the conserved arginine. High-throughput screening showed that PKC412, a multikinase inhibitor, ameliorated K18 Arg90Cys-mediated keratin filament disruption in cells and in the livers of previously described transgenic mice that overexpress K18 Arg90Cys. Furthermore, PKC412 protected cultured A549 cells that express mutant or wild-type K18 and mouse livers of the K18 Arg90Cys-overexpressing transgenic mice from Fas-induced apoptosis. Proteomic analysis of proteins that associated with keratins after exposure of K18-expressing A549 cells to PKC412 showed that nonmuscle myosin heavy chain-IIA (NMHC-IIA) partitions with the keratin fraction. The nonmuscle myosin-IIA (NM-IIA) association with keratins was confirmed by immune staining and by coimmunoprecipitation. The keratin-myosin association is myosin dephosphorylation-dependent; occurs with K8, the obligate K18 partner; is enhanced by PKC412 in cells and mouse liver; and is blocked by hyperphosphorylation conditions in cultured cells and mouse liver. Furthermore, NMHC-IIA knockdown inhibits PKC412-mediated normalization of K18 R90C filaments.
Conclusion:
The inhibitor PKC412 normalizes K18 Arg90Cys mutation-induced filament disruption and disorganization by enhancing keratin association with NM-IIA in a myosin dephosphorylation-regulated manner. Targeting of intermediate filament disorganization by compounds that alter keratin interaction with their associated proteins offers a potential novel therapeutic approach for keratin and possibly other intermediate filament protein-associated diseases.
Insights
A novel kinase inhibitor, PKC412, corrects keratin filament defects caused by mutations. It enhances keratin association with nonmuscle myosin-IIA (NM-IIA), offering a potential therapeutic strategy for intermediate filament diseases.
Area of Science:
- Cell Biology
- Biochemistry
- Molecular Medicine
Background:
- Keratin intermediate filament (IF) proteins are crucial for cell structure.
- Mutations in keratins, particularly at conserved arginine residues, lead to severe disease phenotypes due to filament disruption.
- Understanding the mechanisms underlying keratin filament organization and disruption is vital for developing therapeutic interventions.
Purpose of the Study:
- To identify compounds that can normalize keratin filament organization disrupted by specific mutations.
- To investigate the mechanism by which identified compounds restore keratin filament integrity.
- To explore the therapeutic potential of targeting keratin-myosin interactions for intermediate filament-associated diseases.
Main Methods:
- High-throughput screening of a kinase inhibitor library using cells expressing mutant keratin 18 (K18 Arg90Cys).
- Assessment of keratin filament organization in cells and transgenic mouse models.
- Analysis of protein-protein interactions using proteomics, co-immunoprecipitation, and immune staining.
- Investigation of the role of nonmuscle myosin-IIA (NM-IIA) dephosphorylation in keratin association.
Main Results:
- PKC412, a multikinase inhibitor, effectively ameliorated K18 Arg90Cys-mediated keratin filament disruption in cellular and animal models.
- PKC412 protected cells and mouse livers from Fas-induced apoptosis.
- Proteomic analysis revealed that PKC412 enhances the association of keratins with nonmuscle myosin heavy chain-IIA (NMHC-IIA) in a dephosphorylation-dependent manner.
- NMHC-IIA knockdown abrogated the filament-normalizing effect of PKC412.
Conclusions:
- The kinase inhibitor PKC412 normalizes keratin filament disruption by enhancing keratin association with NM-IIA, regulated by myosin dephosphorylation.
- Targeting intermediate filament disorganization through modulation of keratin-associated protein interactions presents a novel therapeutic avenue for keratinopathies and other IF protein disorders.
More Related Videos
Related Concept Videos
Cytoskeletal Linker Proteins - Plakins
Abnormal Proliferation

